CD86
ENSG00000114013
Target class
Surface antigen
Chromosome
3
Approved drugs
2
Clinical candidates (approved and in development)
2
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- CD86
- Gene name
- CD86 molecule
- Gene symbol
- CD86
- Previous gene symbols
- CD28LG2
- Protein name
- T-lymphocyte activation antigen CD86 (Activation B7-2 antigen) (B70) (BU63) (CTLA-4 counter-receptor B7.2) (FUN-1) (CD antigen CD86)
- B7.2
- B7-2
- Gene biotype
- Protein coding
- Gene family
- CD molecules|V-set domain containing|B7 family
- Target class
- Surface antigen
- Target type
- Human gene
- Tissues expressed in
- 40
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 49.09
- Tissue specificity (Gini)
- 0.626
- Tissue specificity (tau)
- 0.949
- KEGG gene identifiers
- hsa:942
- Protein interaction confidence
- 0.830056
- Protein interaction partners
- 108
- R-HSA-1257604
- R-HSA-2219530
- R-HSA-389356
- R-HSA-389357
- R-HSA-389359
- R-HSA-389513
- R-HSA-6783783
- R-HSA-6811558
- End position
- 122121139
- Start position
- 122055362
- Chromosome
- 3
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein .
- Plasma membrane
- PubMed 7694363
- PubMed 11279501
- Tissue specificity (tau)
- 0.948677
- Expression inequality (Gini)
- 0.625987
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 49.09
- Spleen
- 16.34
- Lung
- 11.95
- Whole Blood
- 11.22
- Brain - Spinal cord (cervical c-1)
- 7.25
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes49.09
- Spleen16.34
- Lung11.95
- Whole Blood11.22
- Brain - Spinal cord (cervical c-1)7.25
- Artery - Aorta5.48
- Adipose - Visceral (Omentum)5.28
- Artery - Coronary5.02
- Nerve - Tibial5.02
- Small Intestine - Terminal Ileum4.93
- Adipose - Subcutaneous4.47
- Adrenal Gland3.08
- Brain - Substantia nigra2.69
- Colon - Transverse2.55
- Artery - Tibial2.4
- Breast - Mammary Tissue2.31
- Bladder2.22
- Colon - Sigmoid2.18
- Fallopian Tube2.16
- Cervix - Endocervix2.15
- Brain - Hypothalamus2.12
- Prostate1.89
- Minor Salivary Gland1.8
- Testis1.66
- Esophagus - Gastroesophageal Junction1.47
And 29 more, listed on the interactive page.
- GO:0006955
- GO:0008284
- GO:0042110
- GO:0050862
- GO:0005886
- GO:0009986
- GO:0070062
- GO:0005515
- GO:0038023
- GO:0048018
Related records
Trials (485)
- A Belatacept Compassionate Use Study for Patients With a Kidney Transplant
- A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
- A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
- A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors
- A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System
- A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms
- A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia
- A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia
- A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata
- A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
- A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine
- A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
- A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
- A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
- A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
- A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
Drugs (2)
- Abatacept T-lymphocyte activation antigen CD86 inhibitor
- Belatacept T-lymphocyte activation antigen CD86 inhibitor